Italy approves human trials of osteoporosis drug raloxifene for coronavirus treatment
Shortpedia
Content Team
Image Credit: Shortpedia
The drug regulator in Italy has given its nod for human clinical trials on raloxifene, a generic osteoporosis drug that is believed to be an effective vaccine against COVID-19 symptoms. Researchers used supercomputers to screen more than 400,000 molecules for identifying the potential drug. Marco Allegretti, head of research at Dompé Farmaceutici, said the drug "inhibits virus replication, thus preventing the worsening of patients."
